Adastra Labs Holdings Ltd. (XTRX) AI Stock Analysis

• Market Cap: C$1.12M
• Dividend Yield: N/A
• Average Volume (3M): 323.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: -33.88%
• EPS Growth: -449.86%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.11
• Shares Outstanding: 5,597,050
• 10 Day Avg. Volume: 51
• 30 Day Avg. Volume: 323
• PEG Ratio: >-0.01
• Price to Book (P/B): 8.69
• Price to Sales (P/S): 0.51
• P/FCF Ratio: 30.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: C$0.21 ▼(-14.58% Downside)
• Action: Reiterated Date: 12/18/25
• Date: Action: Reiterated 12/18/25

The overall stock score is primarily impacted by the company's poor financial performance, which is the most significant factor. Technical analysis provides some moderate support, but the negative valuation metrics further weigh down the score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Specialized B2B extraction and formulation

Adastra Labs operates a focused, specialty business supplying refined cannabinoid ingredients to manufacturers. That B2B ingredient model is durable: it relies on production know-how and contract relationships rather than retail foot traffic, supporting steady demand from downstream brands and potential for long-term supply agreements.

Diversified end-market exposure (consumer & medical)

Serving both consumer and medical product manufacturers gives the company structurally broader demand drivers. Exposure across therapeutic and consumer segments reduces reliance on any single product cycle and can smooth revenue volatility over time as different end markets respond differently to regulation and consumer trends.

Moderate gross profit margin on core processing

A mid-30% gross margin indicates the core extraction and formulation process has reasonable unit economics. Even though operating profitability is currently negative, this gross margin suggests there is a structural ability to generate production-level profit that could flow to the bottom line with tighter operating expense control or scale improvements.

Negative Factors

Declining revenue and large losses

Revenues are declining materially while net margins are deeply negative, indicating the business is shrinking while losing cash on sales. Sustained top-line contraction combined with heavy losses undermines scale economics, limits reinvestment capacity, and makes achieving a durable turnaround more difficult without clear demand or margin recovery.

Negative equity and solvency risk

Negative shareholder equity and an extreme debt-to-equity ratio signal structural balance-sheet weakness and potential solvency stress. This reduces financial flexibility, increases refinancing risk, and can constrain investment or growth initiatives, forcing management to prioritize capital restructuring over strategic opportunities.

Persistent negative operating and free cash flow

Ongoing negative operating and free cash flows show the company is burning cash from core operations. Persistent cash deficits limit the ability to fund working capital, R&D, or capex internally and increase dependence on external financing, which may be costly or unavailable given the weak balance sheet and operating losses.

Adastra Labs Holdings Ltd. Business Overview & Revenue Model

Company Description

Adastra Labs Holdings Ltd. (XTRX) is a Canadian company focused on the research, development, and production of cannabis-related products and services. Operating primarily in the cannabis sector, Adastra Labs engages in the extraction and formulation of cannabis-derived products, offering a range of solutions tailored for both recreational and medical markets. The company's portfolio includes high-quality cannabis extracts, oils, and other innovative products designed to meet the diverse needs of consumers.

How the Company Makes Money

Adastra Labs generates revenue through multiple streams, primarily from the sale of its cannabis extracts and formulated products to both wholesale and retail customers. The company engages in direct sales to licensed cannabis retailers, as well as distribution partnerships with various channels in the cannabis industry. Additionally, Adastra Labs may benefit from contractual agreements for white-label products, where they produce goods for other brands. The company's revenue model is further supported by its ability to develop unique product formulations that cater to evolving consumer preferences, thus enhancing its market competitiveness. Key partnerships with other industry players and compliance with regulatory standards also play a significant role in sustaining and growing its earnings.

Adastra Labs Holdings Ltd. Financial Statement Overview

Summary

The company faces significant financial challenges, with declining revenues and substantial losses. The balance sheet reflects financial instability with negative equity, and cash flow issues further exacerbate the situation, indicating a need for strategic financial restructuring.

Income Statement

The income statement reveals significant challenges, with declining revenue and negative profit margins. The TTM data shows a revenue decrease of 12.28% and a net profit margin of -71.64%, indicating substantial losses. The gross profit margin remains moderate at 35.73%, but EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet is concerning, with a negative stockholders' equity in the TTM period, leading to a high debt-to-equity ratio of -11.50. This indicates financial instability and potential solvency issues. The return on equity is also negative, suggesting that the company is not generating returns on its equity investments.

Cash Flow

Cash flow analysis shows negative operating and free cash flows in the TTM period, with a significant decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is also negative, highlighting inefficiencies in converting income to cash.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Dec 2020
Income Statement
Total Revenue	16.86M	24.84M	22.22M	13.30M	5.63M	2.50M
Gross Profit	5.44M	8.31M	7.57M	6.11M	1.94M	785.58K
EBITDA	-13.19M	-11.21M	-1.41M	-2.62M	-1.39M	-7.07M
Net Income	-14.49M	-13.24M	-3.54M	-4.28M	-2.75M	-8.07M
Balance Sheet
Total Assets	16.01M	19.34M	32.34M	31.80M	28.76M	13.74M
Cash, Cash Equivalents and Short-Term Investments	786.60K	1.30M	1.38M	1.01M	744.54K	1.15M
Total Debt	3.57M	3.62M	3.64M	3.95M	3.59M	2.50M
Total Liabilities	16.96M	17.89M	17.66M	13.57M	6.38M	3.65M
Stockholders Equity	-947.25K	1.45M	14.69M	18.23M	22.37M	10.09M
Cash Flow
Free Cash Flow	-101.81K	410.06K	1.18M	694.07K	-1.64M	-4.63M
Operating Cash Flow	-315.28K	826.23K	1.86M	1.32M	-1.05M	-2.83M
Investing Cash Flow	-714.54K	-416.18K	-681.05K	-1.03M	-262.81K	-1.79M
Financing Cash Flow	-213.55K	-492.29K	-815.12K	-22.55K	915.98K	3.40M

Adastra Labs Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:XTRX, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.22, and below the 200-day MA of 0.24, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 14.65 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:XTRX.

Adastra Labs Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OILS	50 Neutral	C$9.25M	-61.11	11.57%	―	-1.14%	―
STPH	49 Neutral	C$889.83K	2.31	-13.46%	―	―	―
AVCN	46 Neutral	C$23.25M	-11.28	-77.67%	―	2.41%	74.61%
XTRX	45 Neutral	C$1.12M	-0.08	-209.59%	―	-33.88%	-449.86%
LABS	45 Neutral	C$31.56M	-3.89	-19.10%	―	18.06%	34.58%
PCLO	44 Neutral	C$9.23M	-1.68	―	―	15.64%	58.47%